ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2468

The Prevalence Of Sjogren’s Syndrome In Patients With Ankylosing Spondylitis

Ayse Balkarli1, Adem Kucuk2, Sahin Temel3, Tayfun Gungor4, Ramazan Ucar5 and Veli Cobankara6, 1Department of Rheumatology, Pamukkale University School of Medicine, Denizli, Turkey, 2Necmettin Erbakan University, Meram Medical Faculty,Division of Rheumatology, Konya, Turkey, 3Department of Internal Medicine, Pamukkale University, Denizli, Turkey, 4Department of Physical medicine and Rehabilitation, Necmettin Erbakan University, Konya, Turkey, 5Konya Education and Research Hospital, Department ofInternal Medicine, Konya, Turkey, 6Division of Rheumatology, Pamukkale University, Denizli, Turkey

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Sjogren's syndrome and ankylosing spondylitis (AS)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment III

Session Type: Abstract Submissions (ACR)

Background/Purpose : Sjögren’s syndrome (SS) is a chronic autoimmune inflammatory disease that primarily affects exocrine glands with a prevalence of 1% to 4.8. SS mainly affects middle-aged women with a female-male ratio of 9:1. Ankylosing spondylitis (AS) is the prototype of spondyloarthropathy that is characterized by sacro-ileitis, inflammation, enthesitis and also involves peripheral joints, eye and aorta. The prevalence of AS is about 0.5% with a similar female-male ratio. We aimed to evaluate the SS prevalence in patients with AS.

Methods: 143 patients with the diagnosis of AS according to Modified New York Criteria were included in the study. Sicca questionnaire that includes sicca symptoms for SS was performed in all patients. Schirmer test was performed for xerophthalmia and unstimulated salivation test for xerostomia. Rheumatoid factor (RF), antinuclear antibody (ANA), anti-Ro and anti-La antibodies were measured as laboratory tests. Minor salivary gland biopsy was performed in patients with positive xerophthalmia and xerostomia tests and Sicca questionnaire. The presence of SS was assessed according to classification criteria of American-European Consensus Group.

Results: The mean age of patients was 39.6 years old and 73 of them were male. Fourteen (10%) of the patients were diagnosed as SS according to American–European Consensus Group classification criteria. Twenty-three of the patients were undergone minor salivary gland biopsy those fulfilled the three criteria. Fourteen biopsies of the patients were evaluated as pathologically. Three of them were reported as grade IV and 11 of them as grade III sialadenitis according to the criteria of Mason Chisholm. Seven of these 14 patients were male and there was no difference in terms of sex. Only one patient has a positive anti-Ro and anti-La antibodies. However, 13 of patients (except 1 patient) had ANA positivity (> 1/80). There was bilateral sacro-ileitis in MRI of all patients diagnosed as SS.

Conclusion: In our study, we found a high prevalence of SS in patients with AS. ANA positivity was higher in co-existence of SS and AS and it may be a risk factor for SS.

Table 1: General characteristics of the patients

n(%)

Age (years)

39.6

Sex(F/M)

73/70

Duration of disease (years)

6.6±5.3

Drugs

SLZ

IFX ADA

ETA

89(62.2%)

13(9.1%)

19(13.3%)

20(14%)

Xerostomia

51(35.7%)

Xerophthalmia

24(16.8%)


Disclosure:

A. Balkarli,
None;

A. Kucuk,
None;

S. Temel,
None;

T. Gungor,
None;

R. Ucar,
None;

V. Cobankara,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-prevalence-of-sjogrens-syndrome-in-patients-with-ankylosing-spondylitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology